Anzeige
Meldung des Tages: Rüstungsindustrie unter Druck: Warum ein seltenes Metall plötzlich zum Milliardenfaktor wird

Jasper Therapeutics News

Aktie
WKN:  A3E3X1 ISIN:  US4718712023 US-Symbol:  JSPR Branche:  Biotechnologie Land:  USA
1,36 $
-0,02 $
-1,45%
1,1679 € 09.03.26
Depot/Watchlist
Marktkapitalisierung *
22,43 Mio. €
Streubesitz
25,16%
KGV
-0,37
Index-Zuordnung
-

Jasper Therapeutics News

14.11.25 - PR Newswire
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
14.11.25 - PR Newswire
JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR
JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR PR Newswire
14.11.25 - PR Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
14.11.25 - PR Newswire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR PR Newswire
13.11.25 - PR Newswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
12.11.25 - PR Newswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
11.11.25 - PR Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
11.11.25 - PR Newswire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR PR Newswire
09.11.25 - PR Newswire
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
08.11.25 - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper PR Newswire
07.11.25 - PR Newswire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR PR Newswire
07.11.25 - PR Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
04.11.25 - PR Newswire
JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
04.11.25 - PR Newswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
03.11.25 - PR Newswire
JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To Discuss Their Options
JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To ...
30.10.25 - PR Newswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
29.10.25 - PR Newswire
JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
29.10.25 - PR Newswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
29.10.25 - PR Newswire
JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To Discuss Their Options
JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To ...
28.10.25 - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR PR Newswire

Newssuche

Videos

newspaper
10:40 Uhr +50,48%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »